🧪📚 Our team's scoping review of tsDMARD use in pregnancy: From 6,712 records, only 8 studies met criteria (mostly case reports; n=1–116). Evidence was available on tofacitinib, baricitinib & upadacitinib; none on apremilast.

Stenotic large vessel vasculitis is a rare and largely unknown subtype of giant cell arteritis (GCA). Retrospective study of 3,149 patients evaluated long-term outcome and prognosis of GCA with stenotic LVV Arthritis & Rheumatology acrjournals.onlinelibrary.wiley.com/doi/10.1002/...

In a nationwide cohort, spondyloarthritis diagnosis was associated with inflammatory bowel disease preceding & following its diagnosis. Findings also demonstrated temporal variability & highlighted clinical variables associated with SpA in IBD A&R doi.org/10.1002/art.... @predictibd.bsky.social

Randomised controlled trial led by @lli-1.bsky.social shows counselling combined with self-monitoring tools can help people with #RheumatoidArthritis manage their condition better. It can also improve symptoms like fatigue & mood. 🔗Link to paper: pubmed.ncbi.nlm.nih.gov/38152927/

ILD trajectories differ across IIM subsets. In a BC cohort (n=111), our team found that PmPPF occurred in 13.5%, mainly in anti-MDA5+ DM & antisynthetase syndrome, and was absent in scleromyositis. PmPPF associated with ↑ active disease, ↑ rapidly progressive ILD & ↑ transplant (20% vs 1.3%).

New population-based study (n=229,300 T2D): GLP-1RAs & SGLT2is showed no ↑ or ↓ in overall autoimmune rheumatic disease risk vs. DPP4is. But SGLT2is were linked to ~50% ↓ risk of systemic ARDs. Study led by Dr. @derinkaracabeyli.bsky.social. See infographic 👇

JointHealth™ express - #ArthritisAtHome 306 – A discussion on rheum-oncology & artificial intelligence in rheumatology. Watch now: arthritisathome.jointhealth.org?p=6743 #cancer #arthritis #AI @arthritispower.bsky.social @arthritistrainees.bsky.social @schroeder-uhn.bsky.social @achronicvoice.com

Takin hydroxychloroquine as prescribed- reduces hospitalizations snd save dollars!! - as simple as that!!

What is the impact of GLP-1RA & SGLT2i use on risk of developing autoimmune rheumatic diseases (ARD)? Data from a Canadian cohort of adults w/ type 2 diabetes showed SGLT2i use was assoc w/ lower risk of systemic ARDs, but neither GLP-1RA nor SGLT2i treatment was assoc w/ lower non-systemic ARD risk

Our new study finds that early antimalarial adherence (PDC≥0.90) in incident RA/SLE is associated with lower acute care use & costs (BC cohort, 1997–2022; n=25,247): 11% ↓ admissions (RR 0.89), 21% ↓ hosp days (RR 0.79), −$550 CAD costs. Robust to sensitivity analyses. See graphical abstract below.

JointHealth™ express - Now Launching: JointHealth™ Education – #Arthritis and #MentalHealth. Click here to begin the course: bit.ly/JointHealthE... Thank you Dr. Susan Bartlett for your help with this course! 🥰 @schroeder-uhn.bsky.social @arthritistrainees.bsky.social @arthritispower.bsky.social

New Canadian living guidelines address an important gap in cancer care: managing immune checkpoint inhibitors in patients with pre-existing inflammatory arthritis & systemic autoimmune rheumatic diseases. See GRADE-based, disease-specific recommendations in the embedded infographic.

Looking to get active with #arthritis? Yoga might be a great place to start!